Pan-society Presentation of NAFLD Nomenclature Consensus Process

The Liver Meeting®
Washington, DC, United States of America
Sunday, 6 November 2022
16:00 – 18:00
Ballroom ABC

Session Description: In early 2021, a global effort was established to explore the appropriateness and ramifications of a potential re-naming of Nonalcoholic Fatty Liver Disease (NAFLD). In addition to evaluating the current name, if the process determined that a change was appropriate, a key additional goal is to consider which replacement term would best reflect our evolving understanding of the pathophysiology of NAFLD while allowing for the incorporation of future knowledge. In considering the nomenclature, the consensus process sought to better understand the impact of stigma and awareness on patients and caregivers globally.

Over the last two years, a group of 264 global experts from 56 countries have participated in multiple survey rounds utilizing the delphi process. Additionally, a group of 122 participants (54% of survey respondents) from 32 countries participated in an interactive Nomenclature Summit in Chicago, USA in July 2022 to discuss and evaluate the results of the first two delphi rounds. This project has been supported by more than a dozen professional societies and patient groups around the world.

The purpose of this session is to update attendees on the process and key findings of this Delphi process and to engage in discussion with the global community.

Learning Objectives:

- Provide an update on the NAFLD Nomenclature Consensus Process
- Present key findings and proposals developed via the process
- Propose next steps to complete the process

Session time and location: Sunday 4:00-6:00 pm

Chairs: Laurie DeLeve (AASLD), Thomas Berg (EASL), Graciela Castro-Narro (ALEH)

4:00-4:10. Introduction and comments from EASL, AASLD, ALEH leadership/representatives Speaker: DeLeve, Berg, Castro-Narro

4:10-4:20 Consensus process methodology

Speaker: Jeff Lazarus (Consultant, Nomenclature Steering Committee)

4:20-4:30 Importance of Nomenclature from the Patient's Perspective

Speakers: Donna Cryer (Global Liver Institute) and Robert Mitchell-Thain (Liver Patients International)

4:30-4:40 Overview of results Part 1: Stigma, alcohol use and drivers of disease Speaker: Mary Rinella (Nomenclature Steering Committee Co-chair)

4:45-5:05 Panel discussion: Stigma, Alcohol Use and Drivers of Disease

- Panelists: Fasiha Kanwal (US, AASLD) session chair
 - Vincent Wong (Hong Kong, APASL), Vlad Ratziu (France, EASL), Silva Sokooian (Argentina), S.P. Singh (India, SAASL)

5:10-5:20 Overview of results Part 2: Research and development, paediatric issues, nomenclature proposals

Speaker: Phil Newsome, (Nomenclature Steering Committee Co-chair)

5:25-5:50: Panel discussion: Research and Development, Paediatric Issues, Nomenclature Proposals

- Panelists: Sven Francque (Belgium, EASL) session chair
 - Manal Abdelmalek (USA, ACG/AGA/AASLD), Quentin Anstee (UK, EASL), Shiv Sarin (India, APASL), Marco Arrese (Chile, ALEH), Arun Sanyal (US, AASLD)

5:50-6:00 Next steps and Closing remarks

Speaker: Newsome/Rinella